Literature DB >> 28052356

An Overview of the Changing Landscape of Treatment for Advanced Melanoma.

Chung-Shien Lee1, Christan M Thomas2, Kimberly E Ng1.   

Abstract

Melanoma-the deadliest form of skin cancer-leads to thousands of deaths each year. Although melanoma is less common than basal cell and squamous cell skin cancers, melanoma is more dangerous because it is more likely to spread to other parts of the body, such as lymph nodes, if not diagnosed and treated early. Data from the National Cancer Institute indicate a steady rise in new cases of melanoma and, unfortunately, a steady rate in the number of deaths through 2013. Ninety percent of melanomas are linked to inadequate sun protection from ultraviolet rays or the tanning habits of young adults. Over the past 5 years, however, there have been a variety of new pharmacologic treatments for advanced melanoma including immunotherapy, targeted agents (BRAF and MEK inhibitors), and oncolytic viral therapy. In this article, we review the current literature on the treatment of melanoma, with a focus on emerging therapies.
© 2017 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  BRAF inhibitors; CTLA4 inhibitor; MEK inhibitors; PD1 inhibitors; immunotherapy; melanoma

Mesh:

Substances:

Year:  2017        PMID: 28052356     DOI: 10.1002/phar.1895

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  CORR® Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

2.  Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.

Authors:  Megan C Duggan; Kelly Regan-Fendt; Gonzalo N Olaverria Salavaggione; John Harrison Howard; Andrew R Stiff; Julia Sabella; Nicholas Latchana; Joseph Markowitz; Alejandro Gru; Susheela Tridandapani; Ann-Kathrin Eisfeld; Albert de la Chapelle; William E Carson
Journal:  Melanoma Res       Date:  2019-10       Impact factor: 3.599

Review 3.  Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.

Authors:  Caroline A Nebhan; Douglas B Johnson
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-05       Impact factor: 4.512

Review 4.  The Treatment of Advanced Melanoma: Therapeutic Update.

Authors:  Alessia Villani; Luca Potestio; Gabriella Fabbrocini; Giancarlo Troncone; Umberto Malapelle; Massimiliano Scalvenzi
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

5.  Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.

Authors:  Cristina Pellegrini; Ludovica Cardelli; Marina De Padova; Lucia Di Nardo; Valeria Ciciarelli; Tea Rocco; Gianluca Cipolloni; Marco Clementi; Alessio Cortellini; Alessandra Ventura; Pietro Leocata; Maria Concetta Fargnoli
Journal:  Acta Derm Venereol       Date:  2020-01-23       Impact factor: 3.875

6.  Silencing of interferon regulatory factor gene 6 in melanoma.

Authors:  Yoshimasa Nobeyama; Hidemi Nakagawa
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

7.  A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment.

Authors:  Rongzhi Huang; Min Mao; Yunxin Lu; Qingliang Yu; Liang Liao
Journal:  Aging (Albany NY)       Date:  2020-04-20       Impact factor: 5.682

8.  FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Authors:  Sara Ghassemi; Katharina Vejdovszky; Emine Sahin; Lukas Ratzinger; Karin Schelch; Thomas Mohr; Barbara Peter-Vörösmarty; Jelena Brankovic; Andreas Lackner; Alexandra Leopoldi; Diana Meindl; Christine Pirker; Balazs Hegedus; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Petra Heffeter; Walter Berger; Michael Grusch
Journal:  Oncotarget       Date:  2017-09-23

9.  Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis.

Authors:  Lili Huang; Hong Chen; Yu Xu; Jianhua Chen; Zhuqing Liu; Qing Xu
Journal:  Cancer Med       Date:  2020-09-15       Impact factor: 4.452

10.  Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies.

Authors:  Ava Bachari; Terrence J Piva; Seyed Alireza Salami; Negar Jamshidi; Nitin Mantri
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.